Trial Profile
The Effect of Protein Kinase C (PKC) beta Specific Inhibitor on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 26 Nov 2007 New trial record.